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Summary 
We used 2 color analysis system to assess the porphyrin uptake and DNA 
content in 4 established cell lines of glioma employing flow cytometry 
(FCM).  The FCM study revealed porphyrin uptake in all cells, regardless 
of the phase of the cell cycle they were in.  However those in G0/G1 
phase showed moderate uptake of porphyrin and those in the G2/M phase 
showed a higher uptake.  These results indicated the advantage of using 
porphyrin as the carrier of tumor targeting agents as a therapeutic strategy 
for malignant tumors.  
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Introduction 
 Porphyrin is selectively uptaken by tumor cells[1].  Because of 
this property, porphyrin has been used as a tumor targeting agent in 
photodynamic therapy[1].  Some researches using porphyrin as boron 
carrier for boron neutron capture therapy(BNCT) are in progress[2-5].
 The radiosensitivity of tumor cells is an important factor in  
radiation therapy of malignant tumors.  Quiescent cell populations are 
more resistant to gamma ray radiation than all tumor cells in vivo[6].  
Rapidly proliferating  tumors contain a large G2/M cell population which 
is highly radiosensitive in vivo.  The quiescent cell population and G0/G1 
phase cells are radioresistant in vivo.  To achieve cure of the tumor, the 
target of radiotherapy is the G2/M phase population which is not sufficient 
to control the tumor; thus the G0/G1 phase population should also be  
controlled.  In this study, we investigated porphyrin uptake in each cell 
cycle using a double staining technique for porphyrin and DNA content and 
2-dimensional flow cytometry analysis. 
 
Materials and Method 
Cell preparation.   
 A-172, U-251, 9L, ONS cell lines were cultured for several days in 
RPMI 1640  medium(Gibco, New York, NY) or Earle’s minimum 
essential medium(MEM) solution(Gibco, New York, NY).  A-172 and 
U-251 are human glioblastoma cell lines.  ONS is human 
medulloblastoma cell line.  9L is rat gliosarcoma cell line.  They were 
maintained at 37oC in an atmosphere of 5% CO2 in air.  Cells were grown 
in petri dishes and detached with 0.25% trypsin solution. The cells were 
washed with phosphate buffered saline (PBS).  Each cell suspension were 
centrifuged and pellets including about 1x106 cells were cultured in RPMI 
1640 medium with the porphyrin ATX-S10-Na 
(13,17-bis(1-carboxypropionyl) 
carbamoylethyl-8-ethenyl-2-hydroxy-3-hydroxyiminoethylidene-2,7,12, 
18- tetramethyl-porphyrin sodium, Toyo Hakka Co. Ltd., Okayama, Japan) 
at the concentration of 25μg/ml of RPMI 1640 solution for 2 hours at 37˚C 
in an atmosphere of 5% CO2 in air.  The molecular formula of 
ATX-S10-Na is C42H41N7O12Na4, and its molecular weight is 927.79.  
Each cell suspension was centrifuged and the pellets were fixed with 
ice-cooled 70% ethanol  and stored at 4˚C for several hours.  Fixed cells 
were then stained with chromomycin A3 at the concentration of 20μg/ml 
for 1 hour at 4˚C.  The cells were centrifuged and each pellet was 
suspended in PBS. 
Analysis of the cells by fluorescent microscopy and flow cytometry.   
 The uptake of porphyrin and staining of DNA with chromomycin 
A3 were confirmed by fluorescent microscopy (Axiophot, Carl Zeiss Co., 
Ltd., Oberkochen, Germany).  Staining of DNA with chromomycin A3  
was observed as green fluorescence using a band pass filter of 515-565nm.  
The uptake of porphyrin was observed as red fluorescence using a band 
pass filter of more than 590nm. 
 Cell suspensions were filtered  through a mesh of 2mm pore 
(Becton Dickinson, Sanjose, CA) to remove debris or clusters of cells.  
The 1x105 cells of each cell lines was analyzed with flow cytometry. The 
flow cytometric data acquisition was conducted using FACSort (Becton 
Dickinson).  The activated wave length of chromomycin A3 is 
400-460nm(peak:420nm).  The fluorescent wave length of chromomycin 
A3 is 490-610nm(peak:560nm).  The activated wave length of ATX-S10 
is 400-417nm and the peak fluorescent wave length of ATX-S10 is 
677nm[7].  DNA content stained with chromomycin A3 was measured 
with FL2 range.  The fluorescence of ATX-S10 was measured with FL3 
range.  Data were analyzed with Lysis 2 software.  The cells in G0/G1 
and G2/M phase were identified from the histogram of FL2-height. 
 
Results 
Fluorescent microscopy  
 All cell lines stained with chromomycin A3(Fig. 1) and showed 
porphyrin ATX-S10 uptake(Fig. 2).  Porphyrin ATX-S10 seemed to be 
uptaken into both the cytoplasm and nucleus. 
Flow cytometry 
 Figures 3-6 show the dot plot of the relation between FL2 and 
FL3(upper right),  histogram of FL2-height(lower right) and histogram of 
FL3-height(upper left) of A-172, U-251, 9L and ONS cell lines.  The dot 
plot of the relation between FL2 and FL3 showed two clusters of 
cells.  The vertical axis is FL2 fluorescence, the horizontal axis is FL3 
fluorescence.  The FL2-height  histogram of all cells revealed double 
peaks corresponding to cells in the G0/G1 and G2/M phase.  The 
horizontal axis is FL2 fluorescence and vertical axis is cell number.  The 
FL3-height histogram of all cells showed a single peak.  The vertical axis 
is FL3 fluorescence and horizontal axis is cell number.  The mean 
FL3-height of cells in the G2/M phase was higher than that of cells in the 
G0/G1 phase.  This phenomenon was observed in all the cell lines in 
investigated in this study. 
 
Discussion  
 Treatment of malignant tumors requires a multimodality therapy 
involving surgery, radiation, chemotherapy and immumotherapy.  
Malignant brain tumors are the most radioresistant ones.  Surgery 
combined with radiotherapy and/or chemotherapy results in a mean 
survival of 1 year for malignant glioma[8].  BNCT is a bimodal radiation 
therapy using alpha particles induced by neutron capture reaction.  
Thermal neutrons have little effect on normal brain tissue, however,  
tumor tissue containing a boron compound is selectively damaged by alpha 
particles[9].   
 For an effective BNCT, boron uptake into tumor cells is essential.  
In the research of BNCT, boron uptake has been investigated in relation to  
whole tumor tissue.  However the boron uptake and radiosensitivity of 
each cell line probably depends on the phase of the cell cycle.  So the 
effect of BNCT should be examined for each cell line in different phase of 
the cell cycle.  Borocaptate sodium(BSH) and Boronophenyl 
alanine(BPA) are 2 major boron compounds used in BNCT.   BSH is 
selectively uptaken by tumor tissue  and does not cross the intact blood 
brain barrier[10].  The uptake of BSH by tumor cells is not related to the 
cell cycle.  BPA, on the other hand, showed selective uptake by actively 
dividing cells[11].  The tumor control effect of BNCT using BPA was 
better than that using BSH[12].  This difference might be due to the more 
uptake of BPA by G2/M phase cells.   However, BNCT using BPA does 
not include therapy to quiescent cell population.   Cancer therapy requires 
cytotoxic or cytocidal effects not only on proliferating G2/M cells but also 
on G0/G1 cells which may enter the active cell cycle.  After selective 
death of cells in cells cycle, quiescent cells enter the proliferating phase, 
which is called recruitment[13].  BNCT is being performed as 
non-fractionated radiation therapy.   Hence, the target of BNCT should 
include all cells at rest and in cell cycle.   Our data demonstrated the cell 
cycle independent property of porphyrin uptake by tumor cells.  The cells 
in G0/G1 phase showed moderate uptake of porphyrin and the cells in 
G2/M phase showed more uptake of porphyrin than the cells in G0/G1 
phase.  The uptake of porphyrin by each cell was almost proportional to 
the DNA content in each cell.  These results  support the therapeutic 
strategy of BNCT using porphyrin compounds.  The targets of BNCT  
using porphyrin compounds are cells at rest and cells undergoing cell 
division.  On BNCT using porphyrin compounds a more lethal effect is 
expected for cells in the G2/M phase.   
 There are very few reports on porphyrin uptake by tumor cells in 
relation to cell cycle. Fukuda reported the kinetics of porphyrin 
accumulation in cell lines after exposure to delta aminolevulinic acid 
(ALA), the natural precursor of tetrapyrrole biosynthesis[14].  The 
intracellular porphyrin content of cells in the G2/M phase was slightly 
higher than that of cells in the G0/G1 or S phase in this study.  There is 
little obvious cell cycle dependent variation in the synthesis of porphyrin 
from ALA.  They reported the small differences in intracellular porphyrin 
content may be attributed to a slight reduction in the rate of loss of 
porphyrins in cells in the G2/M phase.  Fiedorowicz et al. reported the 
effect of photodynamic therapy with some porphyrin on human leukemic 
cell lines[15].  The photosensitivity of cells was almost the same 
regardless of the phase of they were in, but the cells in the G2/M phase 
were slightly more sensitive than cells on other phases of the cell cycle.  
These results support those of our FCM study. 
 As for the mechanism of porphyrin uptake, the low density 
lipoprotein(LDL) receptor-mediated pathway was reported to be the carrier 
of porphyrin into cells[16].  Tumor cells were shown to have enhanced 
LDL receptor activity and large amounts of LDL receptor on their each cell 
surface[16,17]. The amount of LDL receptor in tumor cells in each phase of 
the cell cycle should be investigated in future studies.  In our results, the 
cell lines showed some different pattern of FACS in each cell line.  This 
may be resulted from the different amounts of LDL receptor on each cell 
line.  And the percentage of G2/M phase is different to each cell line.  
This may be influenced by cell condition or malignancy of each cell line.  
This phenomenon that the porphyrin uptake of cells in the G2/M phase is 
higher than that of cells in the G0/G1 phase was uniformly kept in the cell 
lines in investigated in this study. 
 In summary,  in case of bimodal therapies using porphyrin, 
photo-dynamic therapy and neutron capture therapy,  the uptake of the 
drug by the cells should be considered in relation to the cell cycle.  Future 
studies of neutron capture therapy should be directed to observe the 
cytocidal effect of porphyrin compounds on tumor cells. 
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Legend of figures 
Fig. 1  The photograph of the fluorescent microscopy.  The green 
fluorescence indicate DNA stained with chromomycin A3. 
Fig. 2  The photograph of the fluorescent microscopy.   The red 
fluorescence indicate the porphyrin uptake into tumor cells.  
Fig. 3  The flow cytometry data of A-172 cell line.  The upper left is the 
dot plot of the relation between FL2 and FL3,  the upper right is the 
histogram of FL2-height and the lower left is the histogram of FL3-height.   
Fig. 4  The flow cytometry data of U-251 cell line. 
Fig. 5  The flow cytometry data of 9L cell line. 
Fig. 6  The flow cytometry data of ONS cell line. 
 
  
 
 
